GlassScriptPhysician profile
David J Fehnel
NPI 1609854215
$149,167.18
in general payments reported to CMS, 2019-2025
26 companies · $63K in 2025
The $63K reported for 2025 was more than what 89% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
See the full distribution for Adult Reconstructive Orthopaedic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,638 · 2021: $6,871 · 2022: $5,511 · 2023: $12K · 2024: $49K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $69K · Royalty Or License: $26K · Travel and Lodging: $23K · Food and Beverage: $4,762 · Gift: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $68,932.00 |
| Royalty Or License | $25,651.50 |
| Travel and Lodging | $23,208.30 |
| Food and Beverage | $4,762.21 |
| Gift | $561.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shoulder Innovations, INC. | $117,774.40 | 2021-2025 | Inset System |
| Stryker Corporation | $11,473.93 | 2021-2024 | Aequalis Ascend Flex, Aequalis Perform, Blueprint Patient Specific Instrumentation |
| Medical Device Business Services, INC. | $7,736.45 | 2019-2022 | |
| Wright Medical Technology, INC. | $7,084.31 | 2019-2020 | |
| Depuy Synthes Products, INC. | $2,768.00 | 2019-2021 | |
| Depuy Synthes Sales INC. | $691.41 | 2020-2025 | Dynacord, Fms Duo, Healix Knotless Peek |
| Innovation Technologies INC | $237.99 | 2023-2024 | Irrisept |
| Bioventus LLC | $237.18 | 2021-2025 | Exogen Ultrasound Bone Healing System, Xcell, Exogen Ultrasound Bone Healing System |
| Ferring Pharmaceuticals INC. | $197.42 | 2019-2025 | Euflexxa |
| Smith+Nephew, INC. | $174.50 | 2019-2023 | Bioinductive Implant With Arthroscopic Delivery System - Medium, Bone Anchors With Arthroscopic Delivery System |
| Abbott Laboratories | $148.16 | 2023 | Octrode |
| Baudax Bio INC. | $102.05 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $92.79 | 2022-2025 | Iovera, Zilretta, Exparel |
| Pacira Therapeutics, INC. | $92.42 | 2019 | |
| Orthofix Medical, INC. | $89.77 | 2019-2025 | Physio-Stim |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $53.02 | 2019-2024 | Vistaseal, Stratafix, Surgicel Nu-Knit |
| Zimmer Biomet Holdings, INC. | $35.67 | 2022-2025 | |
| Access Pro Medical, LLC | $26.41 | 2025 | Matriderm |
| Janssen Pharmaceuticals, INC | $22.84 | 2019 | |
| Heraeus Medical, LLC. | $20.25 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $19.75 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.45 | 2020 | |
| Kci USA, INC. | $19.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.18 | 2020 | |
| Acumed LLC | $17.08 | 2024 | Inframe Implant |
| Fidia Pharma USA INC. | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fehnel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.